Text Size

Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

This study has been completed.
Sponsor:
Information provided by:
Cephalon
ClinicalTrials.gov Identifier:
NCT00233675
First received: September 27, 2005
Last updated: January 12, 2006
Last verified: September 2005
History of Changes
  Purpose

To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).


Condition Intervention Phase
General Anxiety Disorder
 Drug: GABITRIL (tiagabine hydrochloride; CEP-6671)
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages Up to 16mg/Day in Adults With Generalized Anxiety Disorder

Resource links provided by NLM:

MedlinePlus related topics: Anxiety
U.S. FDA Resources

Further study details as provided by Cephalon:

  Eligibility

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00233675

  Show 28 Study Locations
Sponsors and Collaborators
Cephalon
Investigators
Study Director: Charles Brown, MD Cephalon
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00233675     History of Changes
Other Study ID Numbers: C6671A/301/AX/US
Study First Received: September 27, 2005
Last Updated: January 12, 2006
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Anxiety Disorders
Mental Disorders
Tiagabine
Anticonvulsants
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
 Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
GABA Agonists
GABA Agents

ClinicalTrials.gov processed this record on June 18, 2013